FY2025 EPS Forecast for Monopar Therapeutics Cut by Analyst

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share estimate for Monopar Therapeutics to ($1.35), down from a previous forecast of ($1.30), while maintaining an Overweight rating and a price target of $74.00.
• Monopar Therapeutics reported a quarterly earnings per share of ($0.35), surpassing analyst expectations of ($0.47), as the stock was recorded trading down 2.9%.
• Insider trading activity included the sale of 42,504 shares worth approximately $1.7 million over the last quarter, reflecting a significant reduction in ownership stakes among key executives.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of Monopar Therapeutics in a research note issued to investors on Wednesday, August 13th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($1.35) for the year, down from their prior estimate of ($1.30). Cantor Fitzgerald currently has a "Overweight" rating and a $74.00 price objective on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. Cantor Fitzgerald also issued estimates for Monopar Therapeutics' FY2026 earnings at ($2.83) EPS.

Other equities research analysts also recently issued research reports about the company. Wall Street Zen raised Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Chardan Capital reiterated a "buy" rating and issued a $60.00 price target on shares of Monopar Therapeutics in a research note on Wednesday, August 13th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $60.00.

Monopar Therapeutics Stock Down 1.5%

Shares of MNPR stock traded down $0.51 during trading hours on Friday, reaching $33.00. The company's stock had a trading volume of 73,723 shares, compared to its average volume of 39,714. The firm's 50 day simple moving average is $37.99 and its 200-day simple moving average is $37.69. The company has a market capitalization of $203.61 million, a price-to-earnings ratio of -9.91 and a beta of 1.05. Monopar Therapeutics has a fifty-two week low of $2.15 and a fifty-two week high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.12.

Insider Buying and Selling

In related news, CEO Chandler Robinson sold 16,800 shares of the firm's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the transaction, the chief executive officer directly owned 73,472 shares of the company's stock, valued at $2,938,880. This trade represents a 18.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christopher M. Starr sold 16,800 shares of the firm's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the transaction, the director directly owned 5,173 shares of the company's stock, valued at approximately $206,920. This represents a 76.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,504 shares of company stock valued at $1,700,160 in the last three months. Insiders own 20.50% of the company's stock.

Hedge Funds Weigh In On Monopar Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. AlphaQuest LLC boosted its stake in Monopar Therapeutics by 46.8% during the 2nd quarter. AlphaQuest LLC now owns 1,784 shares of the company's stock valued at $64,000 after purchasing an additional 569 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Monopar Therapeutics in the 2nd quarter worth approximately $34,000. JPMorgan Chase & Co. boosted its stake in shares of Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after buying an additional 1,821 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Monopar Therapeutics in the 2nd quarter worth approximately $80,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Monopar Therapeutics in the 2nd quarter worth approximately $104,000. Institutional investors and hedge funds own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.